|
Jan Nolta PhD
Professor
University of California, Davis
USA
|
Jan A. Nolta, Ph.D., is the Director of the Stem Cell Program at University of California Davis School of Medicine and directs the Institute for Regenerative Cures and the UC Davis Gene Therapy Center. She is the Scientific Director of the large UC Davis Good Manufacturing Practice Facility, and PI of the California State Umbilical Cord Blood Collection Program. The UC Davis stem cell program has a large number of basic, translational, and clinical scientists collaborating to work toward regenerative medicine-related cures for a spectrum of diseases and injuries. Dr. Nolta is helping UC Davis teams develop numerous clinical trials of gene and cell therapy, with 51 stem cell and/or gene therapy clinical trials currently ongoing, and over twenty in the pipeline. A California Institute for Regenerative Medicine “Alpha Clinic” Award was recently granted to UC Davis to administer FDA-approved stem cell and regenerative medicine therapies.
A scientist with 30 years’ experience with human Hematopoietic and Mesenchymal stem cells, gene therapy, and clinical trial development, Dr. Nolta developed her passion for cellular therapy in the early 90’s by helping to develop and administer the first umbilical cord blood hematopoietic stem cell gene therapy trials for newborns with “bubble baby disease” with her mentor Donald Kohn at the University of Southern California.
Dr. Nolta has published over 200 peer-reviewed manuscripts in the stem cell field, with over 16,700 citations and an H factor of 70 and has authored 30+ book chapters. She has served on over 250 review panels for the NIH and other grant-funding agencies, was editor of the Book "Genetic Engineering of Mesenchymal Stem Cells," and has been Editor-in-Chief for the Journal “Stem Cells” for the past decade.
Major driving forces throughout Dr. Nolta’s career have been to provide service to teams working toward novel cures, fostering teamwork, training the diverse science and healthcare work force of the future, and to continuing to improve and deliver novel cutting-edge therapies for patients who currently have few other options.
A scientist with 30 years’ experience with human Hematopoietic and Mesenchymal stem cells, gene therapy, and clinical trial development, Dr. Nolta developed her passion for cellular therapy in the early 90’s by helping to develop and administer the first umbilical cord blood hematopoietic stem cell gene therapy trials for newborns with “bubble baby disease” with her mentor Donald Kohn at the University of Southern California.
Dr. Nolta has published over 200 peer-reviewed manuscripts in the stem cell field, with over 16,700 citations and an H factor of 70 and has authored 30+ book chapters. She has served on over 250 review panels for the NIH and other grant-funding agencies, was editor of the Book "Genetic Engineering of Mesenchymal Stem Cells," and has been Editor-in-Chief for the Journal “Stem Cells” for the past decade.
Major driving forces throughout Dr. Nolta’s career have been to provide service to teams working toward novel cures, fostering teamwork, training the diverse science and healthcare work force of the future, and to continuing to improve and deliver novel cutting-edge therapies for patients who currently have few other options.